5 studies found for:    23922302 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
Conditions: Ovarian Carcinoma;   Breast Cancer
Intervention: Drug: AZD2281
2 Active, not recruiting Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: AZD2281;   Drug: Liposomal Doxorubicin
3 Active, not recruiting Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer
Condition: Ovarian Neoplasm
Intervention: Drug: KU-0059436 (AZD2281)(PARP inhibitor)
4 Active, not recruiting Phase I Comparative Bioavailability Study
Condition: Solid Tumors
Intervention: Drug: AZD2281
5 Active, not recruiting A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)
Conditions: Ovarian Neoplasms;   BRCA1 Protein;   BRCA2 Protein
Intervention: Drug: KU-0059436 (AZD2281)(PARP inhibitor)

Indicates status has not been verified in more than two years